Primed for attack: Vaccine tech maker gets $11M shot to battle infectious disease
Traditional antibody-based vaccines, as a basic principle, prevent infection. UK-based Emergex’s technology doesn’t care if you do contract the infection — it is engineered to ensure …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
